

## MATERIALS LICENSE

Amendment No. 53

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s); and to import such byproduct and source material. This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

**"OFFICIAL RECORD COPY"**

## Licensee

1. Newton-Wellesley Hospital  
  
2. 2014 Washington Street  
Newton Lower Falls, Massachusetts 02162

In accordance with application dated  
April 23, 1985

3. License number 20-02615-01 is amended in its  
entirety to read as follows:

4. Expiration date July 31, 1990

5. Docket or  
Reference No. 030-018486. Byproduct, source, and/or  
special nuclear material7. Chemical and/or physical  
form8. Maximum amount that licensee  
may possess at any one time  
under this license

- A. Any byproduct material  
listed in Groups I and  
II of Schedule A, Section  
35.100 of 10 CFR 35  
B. Any byproduct material  
listed in Group III of  
Schedule A, Section  
35.100 of 10 CFR 35  
C. Any byproduct material  
listed in Group IV of  
Schedule A, Section  
35.100 of 10 CFR 35  
D. Any byproduct material  
listed in Group V of  
Schedule A, Section  
35.100 of 10 CFR 35  
E. Any byproduct material  
listed in Section 31.11(a)  
of 10 CFR 31  
F. Xenon 133

- A. Any radiopharmaceutical  
listed in Groups I and  
II of Schedule A, Section  
35.100 of 10 CFR 35  
B. Any form listed in Group  
III of Schedule A, Section  
35.100 of 10 CFR 35  
C. Any radiopharmaceutical  
listed in Group IV of  
Schedule A, Section  
35.100 of 10 CFR 35  
D. Any radiopharmaceutical  
listed in Group V of  
Schedule A, Section  
35.100 of 10 CFR 35  
E. Prepackaged kits

- A. As necessary for uses  
authorized in Subitem  
9.A.  
B. 3 curies of each  
byproduct material  
authorized in Subitem 6.B.  
C. As necessary for uses  
authorized in Subitem 9.C.  
D. As necessary for uses  
authorized in Subitem 9.D.  
D. 3 millicuries of each  
byproduct material  
authorized in Subitem 6.E.  
F. 200 millicuries

- F. Gas or gas in solution  
that is the subject of  
an active (i.e., not  
withdrawn or terminated)  
"New Drug Application"  
(NDA) approved by FDA  
or an active (i.e., not  
withdrawn, terminated or  
on "clinical hold")  
"Notice of Claimed In-  
vestigational Exemption  
for a New Drug" (IND)  
that has been accepted  
by FDA

- G. Sealed source (Gulf Nuclear, G. Not to exceed 300  
Inc., Model GD-1 per source

8509190151 850906  
REG1 LIC30  
20-02615-01 PDR

- G. Gadolinium 153

ML10

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License number

20-02615-01

Docket or Reference number

030-01848

Amendment No. 53

(continued)

H. Iodine 125

H. Sealed source (AECL Models  
C-234 or C-324 or Amersham  
Model IMC.P2)

H. Not to exceed 1500  
per source

**9. Authorized use**

- A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100, Title 10, Code of Federal Regulations.
- B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- C. Any therapeutic procedure listed in Group IV of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- D. Any therapeutic procedure listed in Group V of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- E. In vitro studies.
- F. Blood flow and pulmonary function studies.
- G. For use in Lunar Radiation Corporation Model DP3 bone mineral analyzer.
- H. For use in Lunar Radiation Corporation Model SP2 bone mineral analyzer.

**CONDITIONS**

- 10. Licensed material shall be used only at the licensee's facilities, at 2014 Washington Street, Newton Lower Falls, Massachusetts.
- 11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions, and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."
- 12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Harold Simon, M.D.

Groups I, II, III, IV, and V

In vitro studies

Xenon 133

Iodine 125 and Gadolinium 153 sealed sources for  
diagnosing bone maladies

Ralph Scott, M.D.

Group I

In vitro studies

Theodore Spielberg, M.D.

Iodine 131 for treatment of hyperthyroidism and  
cardiac dysfunction

- 13. Licensed material shall be used in accordance with the provisions of Section 35.14(b)(c)(e) and (f) of Title 10, Code of Federal Regulations.

**MATERIALS LICENSE**  
**SUPPLEMENTARY SHEET**

License number

20-02615-01

Docket or Reference number

030-01848

Amendment No. 53

(continued)

**CONDITIONS**

14. For a period not to exceed sixty (60) days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:

- (a) Has the prior written permission of the hospital's Administrator and its Medical Isotopes Committee, and
- (b) Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and
- (c) Performs only those procedures for which he is specifically authorized by a Nuclear Regulatory Commission license.

The licensee shall maintain for the inspection by the Commission, copies of the written permission specified in subitem (a) above and of the license(s) specified in subitems (b) and (c) above. These records shall be maintained for five (5) years from the time the licensee grants its permission under subitem (a) above.

15. Sealed sources containing licensed material shall not be opened.

16. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:

- A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of ten (10) half-lives.
- B. Prior to disposal as normal waste, radioactive waste shall be monitored to determine that its radioactivity cannot be distinguished from background with typical low-level laboratory survey instruments. All radiation labels will be removed or obliterated.
- C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

17. A. (1) Each sealed source in a bone mineral analyzer shall be tested for leakage and/or contamination at intervals not to exceed six months. In the absence of a certificate from a transferor indicating that a test has been made within six months prior to the transfer, a sealed source received from another person shall not be put into use until tested.

(2) Notwithstanding the periodic leak test required by this condition, any licensed sealed source is exempt from such leak tests when the source contains 100 microcuries or less of beta and/or gamma emitting material or 10 microcuries or less of alpha emitting material.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License number

20-02615-01

Docket or Reference number

030-01848

Amendment No. 53

(17. continued)

**CONDITIONS**

- (3) The periodic leak test required by this condition does not apply to sealed sources that are stored and not being used. The sources excepted from this test shall be tested for leakage prior to any use or transfer to another person unless they have been leak tested within six months prior to the date of use or transfer.
- B. The test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. The test sample shall be taken from the sealed source or from the surfaces of the device in which the sealed source is permanently mounted or stored on which one might expect contamination to accumulate. Records of leak test results shall be kept in units of microcuries and maintained for inspection by the Commission.
- C. If the test reveals the presence of 0.005 microcurie or more of removable contamination, the licensee shall immediately withdraw the sealed source from use and shall cause it to be decontaminated and repaired or to be disposed of in accordance with Commission regulations. A report shall be filed within 5 days of the test with the U. S. Nuclear Regulatory Commission, Region I, 631 Park Avenue, King of Prussia, Pennsylvania 19406, describing the equipment involved, the test results, and the corrective action taken.
- D. Tests for leakage and/or contamination shall be performed by the licensee or by other persons specifically authorized by the Commission or an Agreement State to perform such services.
18. Patients containing Iodine 131 for the treatment of thyroid carcinoma shall remain hospitalized until the residual activity is 30 millicuries or less.
19. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated April 23, 1985 and letter dated June 25, 1985. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

For the U.S. Nuclear Regulatory Commission

Original Signed By:

John E. Glenn

By

Nuclear Materials Safety and  
Safeguards Branch, Region I  
King of Prussia, Pennsylvania 19406

Date

SEP 06 1985